Table 2.
Baseline characteristics: medications and HTN in different subgroups.
| Characteristics | NGT | GC | GCC | PC | PCC |
|---|---|---|---|---|---|
| n | 34 | 27 | 32 | 21 | 32 |
| Lipid lowering Agents | — | 23 | 30 | 13 | 28 |
| Aspirin | — | 20 | 25 | 13 | 29 |
| Metformin | — | 22 | 26 | 18 | 19 |
| Sulphonylurea | — | 7 | 14 | 16 | 19 |
| PPAR γ agonists | — | 0 | 3 | 1 | 1 |
| GLP 1 analogs | — | 2 | 1 | 2 | 1 |
| DPP IV inhibitors | — | 0 | 3 | 2 | 2 |
| Insulin | — | 2 | 9 | 11 | 23 |
| ACE inhibitors | — | 16 | 20 | 8 | 19 |
| ARB | — | 4 | 8 | 8 | 7 |
| HTN | — | 17 | 6 | 7 | 20 |
PPAR γ agonists, Peroxisome proliferator-activated receptor gamma agonists, GLP-1 analogs, Glucagon-like peptide-1 analogs, DPP IV inhibitors, Inhibitors of dipeptidyl peptidase 4, ACE inhibitor, Angiotensin-converting-enzyme inhibitor, ARB, angiotensin receptor blockers, HTN, Hypertension.